Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human cytomegalovirus immunoglobulin
- Development stage
- Approved
- Lead developer
- Biotest
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CMV Ig (cytomegalovirus immunoglobulin) is a purified, sterile, plasma-derived hyperimmune globulin preparation containing high titers of immunoglobulin G (IgG) antibodies directed against cytomegalovirus (CMV). Derived from pooled human plasma of donors selected for high anti-CMV antibody levels, CMV Ig provides immediate passive immunity to prevent or attenuate CMV infection and disease. It is primarily indicated for the prophylaxis of CMV disease in high-risk solid organ transplant recipients (such as kidney, liver, lung, pancreas, and heart transplants) and bone marrow transplant recipients, often used in combination with antiviral therapies like ganciclovir. It is also utilized as an adjunctive treatment for established, severe CMV infections, such as CMV pneumonitis.
- Brand names
- CMV Immunoglobulin-VFCytoGamCytotectMegalotectNeocytotect
- Other names
- CMV IgCMV-IGCMV-IGIVCMV-IVIgCMVIGcytomegalovirus immune globulincytomegalovirus immune globulin intravenous humancytomegalovirus immunoglobulinhuman cytomegalovirus immune globulinhuman cytomegalovirus immunoglobulin
02
Targets
C1Q (Complement C1q)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)HCMV Pentamer (HCMV pentameric glycoprotein complex)Human cytomegalovirus glycoprotein H/glycoprotein L/glycoprotein O complex (HCMV gH/gL/gO)Human cytomegalovirus glycoprotein M/glycoprotein N complexgB (Human cytomegalovirus glycoprotein B)
Beyond the preview
Go deeper on human cytomegalovirus immunoglobulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human cytomegalovirus immunoglobulin.